Halozyme Therapeutics, Inc.
General ticker "HALO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.8B (TTM average)
Halozyme Therapeutics, Inc. follows the US Stock Market performance with the rate: 38.1%.
Estimated limits based on current volatility of 1.8%: low 66.24$, high 68.71$
Factors to consider:
- Total employees count: 350 as of 2024
- Top business risk factors: Regulatory and compliance, Dependence on ENHANZE technology, Public health crises, Transaction risks, Operational and conduct risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [57.26$, 85.25$]
- 2026-12-31 to 2027-12-31 estimated range: [61.58$, 90.84$]
Financial Metrics affecting the HALO estimates:
- Negative: with PPE of 16.4 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 33.58 > 18.39
- Positive: 6.59 < Operating cash flow per share per price, % of 8.04
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.15 > 6.06
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 1.93 <= 19.24
- Positive: Interest expense per share per price, % of 0.22 <= 0.73
- Negative: Industry earnings per price (median), % of -13.66 <= 0
Short-term HALO quotes
Long-term HALO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $829.25MM | $1,015.32MM | $1,396.61MM |
| Operating Expenses | $491.68MM | $463.85MM | $927.61MM |
| Operating Income | $337.57MM | $551.48MM | $469.01MM |
| Non-Operating Income | $10.76MM | $5.66MM | $-2.13MM |
| Interest Expense | $18.76MM | $18.09MM | $18.13MM |
| R&D Expense | $76.36MM | $79.05MM | $81.49MM |
| Income(Loss) | $348.33MM | $557.13MM | $466.88MM |
| Taxes | $66.73MM | $113.04MM | $149.99MM |
| Net Income(Loss)* | $281.59MM | $444.09MM | $316.89MM |
| Stockholders Equity | $83.81MM | $363.82MM | $48.81MM |
| Inventory | $127.60MM | $141.86MM | $176.47MM |
| Assets | $1,733.27MM | $2,063.48MM | $2,525.32MM |
| Operating Cash Flow | $388.57MM | $479.06MM | $651.56MM |
| Capital expenditure | $15.29MM | $10.70MM | $6.97MM |
| Investing Cash Flow | $-96.91MM | $-262.72MM | $-545.81MM |
| Financing Cash Flow | $-407.99MM | $-218.86MM | $-85.17MM |
| Earnings Per Share** | $2.13 | $3.50 | $2.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.